Most patients with Valley Fever recover with no treatment and
will have life-long immunity. In severe cases, especially in those patients with rapid and extensive primary illness, those
who are at risk for dissemination of disease, and those who have disseminated disease, antifungal drug therapy is used. The
type of medication used and the duration of drug therapy is determined by the severity of disease and response to the therapy.
The medications used include ketoconazole, itraconazole and fluconazole in chronic, mild-to-moderate disease, and amphotericin
B, given intravenously or inserted into the spinal fluid, for rapidly progressive disease. Although these treatments are often
helpful, evidence of disease may persist and years of treatment may be required.
Surgical removal of cavities in the lung from Valley
Fever is sometimes necessary. Surgical drainage of Valley Fever abscesses in bones or joints is also commonly performed.
BioMed Central - Coccidioidomycosis
Coccidioidomycosis is caused by a dimorphous fungus, Coccidioides. It has recently been determined that Coccidioides consists of two species, C. immitis and C. posadii. Although these organisms are genetically distinct and do not exchange DNA, they cannot be distinguished phenotypically and the disease or immune response to the organisms is indistinguishable. Coccidioides grows as a mycelium in the soil and is well-defined geographically, primarily in the Southwestern United States, northwestern Mexico, and Argentina. Infection is usually the result of activities that cause the infectious parts of the fungus to become airborne and inhaled by a susceptible host. The main risk factors for acquiring infection with Coccidioides are activities that bring one into contact with dust from uncultivated soil in the endemic areas.
Pfizer - Global Health
The Diflucan Partnership Program (DPP) is one example of Pfizer's commitment to increasing access to medicines and to building strong partnerships with the public sector and civil society to enhance the capacity of developing countries to provide medicines to patients in need. The program is a unique public-private initiative to treat patients with Diflucan in collaboration with ministries of health, local clinicians, and non-governmental organizations (NGOs).
In participating countries, the Diflucan Partnership Program has:
Treated approximately 65,000 patients for cryptococcal meningitis and esophageal candidiasis;
Distributed more than 4 million free doses of Diflucan to participating insitutions;
Trained 18,000 healthcare workers in the diagnosis and treatment of fungal opportunistic infections;and
Broadened the collaboration to include i nternational institutions such as the Centers for Disease Control, Axios International, International Dispensary Association, Interchurch Medical Assistance, and the International Association of Physicians in AIDS Care.
Valley Fever .... The Cure, A Remedy for Valley Fever!
My mother's last wish before she passed away was that my dad's discovery not be allowed to die with her. So, here's the story.
Disclaimer: The information presented on these pages is provided for educational purposes only. There are no warranties either expressed or implied regarding the outcome of the treatment methodology identified herein.
As with all health decisions, you should consult with your physician regarding specific treatment plans.